Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets
World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated...
Neurology
Assure Holdings Corp. Prices $6.2 Million Underwritten Public Offering of Common Stock
DENVER, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (NASDAQ: IONM) ("Assure Holdings" or the "Company"), a provider of...
Assure Holdings Corp. Announces Proposed Underwritten Public Offering of Common Stock
DENVER, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (NASDAQ: IONM) ("Assure Holdings" or the "Company"), a provider of...
Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
AUSTIN, Texas, Aug. 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis
VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in Europe for the treatment of adults living with generalized...
Assure Holdings Sets Second Quarter 2022 Conference Call for Monday, August 15, 2022, at 4:30 p.m. ET
DENVER, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative...
Key Collaboration and Distribution Agreement Signed With Major Partner To Advance Sofwave™ Sales In China’s Growing $29 Billion Aesthetic Medicine Market
Partnership is with HTDK Group, wholly owned by Warburg PincusHTDK Group is a leading healthcare solutions provider which sells into...
Xenon Pharmaceuticals to Present at the 13th Annual Wedbush PacGrow Healthcare Conference
BURNABY, British Columbia, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that...
TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
Conference call to be held today, August 8, 2022 at 8:30 AM ETNEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) --...
electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference
ROCKAWAY, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that...
electroCore to Announce Second Quarter 2022 Financial Results on August 4
ROCKAWAY, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that...
GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies
SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for...
Xequel Bio Expands Leadership Team with Appointments of Dr. Michael J. Brubaker as Chief Scientific Officer and Tony C. Tipton as Chief Operating Officer
Seasoned Biopharma Executives Bring Significant Clinical Development and Commercial Expertise Michael Brubaker, Ph.D., Xequel Bio, Chief Scientific Officer “The addition...
Orphalan announces enrolment of the first five patients in the International Wilson’s Disease Patient Registry (“iWD Registry”)
Orphalan announces enrolment of the first five patients in the International Wilson's Disease Patient Registry (“iWD Registry”) World’s first global...
Ashvattha Therapeutics Announces Publication of Data in Science Translational Medicine from Phase 2a Clinical Trial for OP-101 in Severe COVID-19 Showing Significant Reduction in Inflammatory and Neuroinflammatory Markers and Improved Clinical Outcomes
– Data showed OP-101 delivered intravenously may have the potential to treat systemic inflammation and neuronal injury, reducing morbidity and...
Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials
HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapiesTOKYO,...
Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities
FDA clears Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare...
Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based PET Tracer [18F]OP-801 at the 2022 Alzheimer’s Association International Conference (AAIC)
– Scientific collaborators at Stanford University will present preclinical data on the sensitivity of OP-801 in comparison to TSPO-PET for...
Digital Health Technologies Market to Garner USD 68.89 Billion by 2029: Industry Analysis by Technology, Application, Types, Key Segment, Challenges and Future Growth Prospects
MELBOURNE, Australia, July 14, 2022 /PRNewswire/ -- A Qualitative Research Study accomplished by Data Bridge Market research's database of 350...
MCRA Assists NeuroMetrix with obtaining FDA Breakthrough Device Designation and Marketing Authorization in One Year
MCRA's Regulatory Team was retained by NeuroMetrix to lead the strategy and development of a De Novo submission to the...